Literature DB >> 33447568

Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation.

Rui Ji1, Yong Li1, Chenyun He1, Xinghua Zhu2, Aiqin He1, Yunyan Lu1.   

Abstract

BACKGROUND: The purpose of this study was to explore the clinical significance of CA125, CK7, CK20, ER, PR, C-erbb2, and P-gp in ovarian cancer.
METHODS: Ovarian cancer patients were recruited from Nantong Cancer Hospital between March 2006 and July 2011. The expressions of CA125, CK7, CK20, ER, PR, C-erbb2, and P-gp were determined by immunohistochemistry (IHC).The chi-square test (χ2) was used to analyze the correlation between each index and the clinical characteristics of the patients. The patients were followed up to record the cancer recurrence time. The Kaplan-Meier method was used to map the cumulative recurrence-free survival (RFS) rate, and COX regression analysis was established for multivariate analysis.
RESULTS: The results of IHC showed that the positive expression rates of CA125, CK7, ER, C-erbb2, and P-gp in malignant ovarian cancer tissues were significantly higher than those in benign ovarian cancer tissues. CA125 expression in malignant ovarian cancer was significantly correlated with the age of patients and the Federation of International Gynecology and Obstetrics (FIGO) stage. CK7 expression in malignant ovarian cancer was significantly correlated with the age, tissue differentiation, and number of residual lesions. CK20 expression in malignant ovarian cancer was significantly correlated with the age and tissue differentiation of the patients. ER expression in malignant ovarian cancer was significantly correlated with the age of patients and FIGO stage. PR expression in malignant ovarian cancer was significantly correlated with the age of the patients. C-erbb2 expression in malignant ovarian cancer was significantly correlated with the age of the patients. P-gp expression in malignant ovarian cancer was significantly correlated with the patient age, pathological type, and tissue differentiation. The expression of CA125, CK7, CK20, C-erbb2, and P-gp had significant effects on the prognosis of patients with ovarian cancer. The COX regression analysis showed that P-gp was an independent risk factor for ovarian cancer.
CONCLUSIONS: In malignant ovarian cancer tissues, CA125, CK7, CK20, ER, PR, C-erbb2, and P-gp are over-expressed. The expression of P-gp is an independent risk factor for ovarian cancer, and it can be an important target for the treatment of malignant ovarian cancer. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  C-erbb2; CA125; CK20; CK7; COX; Kaplan-Meier; Ovarian cancer; P-gp; estrogen receptor (ER); progesterone receptor (PR)

Year:  2020        PMID: 33447568      PMCID: PMC7804549          DOI: 10.21037/gs-20-811

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  42 in total

1.  DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes.

Authors:  M Hattori; H Sakamoto; K Satoh; T Yamamoto
Journal:  Cancer Lett       Date:  2001-08-28       Impact factor: 8.679

Review 2.  Principles of clinical management of ovarian cancer.

Authors:  Tatiana V Gorodnova; Anna P Sokolenko; Ekatherina Kuligina; Igor V Berlev; Evgeny N Imyanitov
Journal:  Chin Clin Oncol       Date:  2018-12

3.  Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary.

Authors:  So Yeon Park; Hee Sung Kim; Eun Kyung Hong; Woo Ho Kim
Journal:  Hum Pathol       Date:  2002-11       Impact factor: 3.466

4.  Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers.

Authors:  Robert C Bast; Steven Skates; Anna Lokshin; Richard G Moore
Journal:  Int J Gynecol Cancer       Date:  2012-05       Impact factor: 3.437

5.  Expression of cytokeratins 7 and 20 in ovarian neoplasia.

Authors:  Helen P Cathro; Mark H Stoler
Journal:  Am J Clin Pathol       Date:  2002-06       Impact factor: 2.493

6.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

7.  Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.

Authors:  S E Kabawat; R C Bast; A K Bhan; W R Welch; R C Knapp; R B Colvin
Journal:  Int J Gynecol Pathol       Date:  1983       Impact factor: 2.762

8.  Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors.

Authors:  Kyoko Kawamura; Yoshihiro Komohara; Kiyomi Takaishi; Hidetaka Katabuchi; Motohiro Takeya
Journal:  Pathol Int       Date:  2009-05       Impact factor: 2.534

9.  Multiple drug resistance parameter expression in ovarian cancer.

Authors:  F Joncourt; K Buser; H Altermatt; M Bacchi; A Oberli; T Cerny
Journal:  Gynecol Oncol       Date:  1998-08       Impact factor: 5.482

10.  High LIN28A and PLK4 co‑expression is associated with poor prognosis in epithelial ovarian cancer.

Authors:  Yao He; Hui Wang; Meina Yan; Xinxin Yang; Rong Shen; Xiaoge Ni; Xiaokun Chen; Peifang Yang; Miao Chen; Xiaodong Lu; Genbao Shao; Xiaoming Zhou; Qixiang Shao
Journal:  Mol Med Rep       Date:  2018-10-16       Impact factor: 2.952

View more
  2 in total

1.  An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.

Authors:  Wen-Fang Cheng; Kuan-Ting Kuo; Yu-An Chen; Chen-Yu Lu; Chen-Wei Yu; Hon-Nerng Ho; Hsin-Fu Chen; Szu-Hua Pan
Journal:  BMC Cancer       Date:  2022-09-10       Impact factor: 4.638

2.  Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.

Authors:  Di Zhang; Dan Zou; Yue Deng; Lihua Yang
Journal:  J Ovarian Res       Date:  2021-09-15       Impact factor: 4.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.